Tethys Bioscience Obtains $25,000,000 Series D Round

  • Feed Type
  • Date
  • Company Name
    Tethys Bioscience
  • Mailing Address
    5858 Horton Street Emeryville, CA 94608
  • Company Description
    The company has become a pioneer in the discovery, development and value creation of novel biological markers for the clinical diagnostics marketplace: Biomarkers. The company believes there is a large unmet need in both the discovery of potentially important biomarkers and the eventual use of them in routine clinical practice for many significant diseases.
    Tethys has built expertise, created significant intellectual property, and is executing its business plan around three key areas: Biomarker Discovery, Clinical Validation and Value Creation. Tethys is focused upon biomarkers that yield significant savings to the health care system and improve the quality of life for patients.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series D
  • Proceeds Purposes
    “These funds will enable Tethys to respond to rapidly increasing customer demand for the PreDx DRS from the large primary care physician market and to broaden our reach to these clinicians through new commercialization strategies,” said Mickey Urdea, Ph.D., Chairman and CEO of Tethys.
  • M&A Terms
  • Venture Investor
    Aeris Capital AG
  • Venture Investor
    Wasatch Funds
  • Venture Investor
    Mohr Davidow Ventures
  • Venture Investor
    Kleiner Perkins Caufield & Byers
  • Venture Investor
    Intel Capital

Trending on Xconomy